Equity Issuances

CaliberCos Inc. issued up to an aggregate of $10,333,203 of shares of the Company’s Class A common stock of common stock to R.F. Lafferty & Co., Inc. and The Benchmark Company, LLC for commissions in cash at a rate of up to 3.0%.

“On September 17, 2025, the Company entered into an At-The-Market Offering Agreement (the “Sales Agreement”) with R.F. Lafferty & Co., Inc. and The Benchmark Company, LLC (together, the “Managers”) to create an at-the-market equity program under which it may sell up to an aggregate of $10,333,203 of shares of the Company’s Class A common stock, par value $0.001 per share (the “Shares”), from time to time through the Managers, as sales agents, subject to any applicable limits when using Form S-3 (the “ATM Offering”).”

CaliberCos Inc. issued 15,868 shares of Series B Preferred Stock of preferred stock to Mast Hill Fund, L.P. for gross proceeds to the Company of $15,868,000.

“On September 11, 2025, CaliberCos Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with Mast Hill Fund, L.P. (the “Investor”) as the purchaser, pursuant to which the Company issued the Investor 15,868 shares of Series B Preferred Stock at a per share purchase price of $1,000 for gross proceeds to the Company of $15,868,000.”

Trade Desk, Inc. issued common stock.

“the stockholders of the Company approved the amendment and restatement of the Company’s articles of incorporation”

Grayscale Stellar Lumens Trust (XLM) issued 15,000 Shares of common stock to selected accredited investors for 1,283,889.5114356 XLM representing $534,986.

“Since the sales reported on the most recently filed Current Report on Form 8-K by Grayscale Stellar Lumens Trust (XLM) (the “Trust”), the Trust issued 15,000 Shares at varying prices determined by reference to its NAV per Share to selected “accredited investors,” within the meaning of Rule 501 of Regulation D under the Securities Act of 1933, as amended (the “Securities Act”), in private placement transactions exempt from the registration requirements of the Securities Act pursuant to Rule 506(c) thereunder for an aggregate of 1,283,889.5114356 XLM representing $534,986.”

Banzai International, Inc. issued convertible note to YA II PN, LTD. for principal amount of $2,000,000.

“On September 16, 2025, Banzai International, Inc. (“ Banzai ” or the “ Company ”) entered into a Convertible Promissory Note (the “ Note ”) with YA II PN, LTD., a Cayman Islands exempt limited company (the “ Investor ”) in principal amount of $2,000,000 (the “ Original Principal Amount ”) to the Company, to be used as an advance under the outstanding Standby Equity Purchase Agreement entered into on December 14, 2023 by the Company and the Investor (the “ SEPA ”).”

AMAZE HOLDINGS, INC. issued convertible note to certain holders of its secured original issue discount notes for $4,043,234.24 total consideration.

“$4,143,234 in aggregate principal amount of senior secured original issue discount convertible promissory notes (the “New Convertible Notes”) for a total consideration of $4,043,234.24 by (i) exchanging with the Company approximately $3,043,234 of aggregate outstanding principal amount, plus accrued interest, of Prior Notes held by them and (ii)”

AtlasClear Holdings, Inc. issued Convertible promissory notes, convertible into equity at the closing of a Qualified Financing at the same per share price as the securities sold in the Qualifie of convertible note to certain institutional investors for gross purchase price of $3,000,000 in cash, reflecting a 20% original issue discount on the principal amount of $3,600,000.

“On September 16, 2025, AtlasClear Holdings, Inc. (the “Company”) entered into separate securities purchase agreements (each, a “Securities Purchase Agreement”) with certain institutional investors (each, an “Investor”) under which the Company agreed to issue and sell, in a private placement, convertible promissory notes (each, a “Note” and collectively, the “Notes”) for an aggregate principal amount of $3,600,000, for a gross purchase price of $3,000,000, reflecting a 20% original issue discount, before fees and other expenses.”

WESBANCO INC issued 9,200,000 depositary shares, each representing a 1/40th interest in a share of the Company’s 7.375% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, S of preferred stock to the public for aggregate gross proceeds of $230,000,000 ($25 per depositary share).

“on September 17, 2025, Wesbanco, Inc. (the “Company”) completed its previously disclosed public offering (the “Offering”) of 9,200,000 depositary shares (the “Depositary Shares”), each representing a 1/40th interest in a share of the Company’s 7.375% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series B, no par value per share (the “Series B Preferred Stock”), with a liquidation preference of $1,000.00 per share (equivalent to $25.00 per Depositary Share).”

Hyperscale Data, Inc. issued aggregate of 260 shares of Class A Common Stock of common stock for upon conversion of an equal number of shares of Class B common stock.

“issued an aggregate of 260 shares of Class A Common Stock upon conversion of an equal number of shares of Class B common stock”

Hyperscale Data, Inc. issued aggregate of 8,700,000 shares of common stock for upon conversion of approximately 3,505.32 shares of Series B Convertible Preferred Stock.

“issued an aggregate of 8,700,000 shares of its Class A common stock (" Class A Common Stock ") upon conversion of approximately 3,505.32 shares of Series B Convertible Preferred Stock”

SMITH MICRO SOFTWARE, INC. issued up to a number of shares of Common Stock equal to the principal amount of such Note divided by the Market Price (as defined under Nasdaq regulations) of the Com of warrant to Timothy C. Huffmyer for The Company will receive an amount equal to $0.125 per Warrant Share for each Warrant issued.

“Each Note shall be accompanied by the issuance by the Company of an unregistered warrant (each, a “Warrant”) to purchase up to a number of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) equal to the principal amount of such Note divided by the Market Price (as defined under Nasdaq regulations) of the Company’s Common Stock on the date of issuance (the “Warrant Shares”). The Company will receive an amount equal to $0.125 per Warrant Share for each Warrant issued.”

SMITH MICRO SOFTWARE, INC. issued up to a number of shares of Common Stock equal to the principal amount of such Note divided by the Market Price (as defined under Nasdaq regulations) of the Com of warrant to Smith Living Trust, for which William W. Smith, Jr. and Dieva L. Smith serve as co-trustees for The Company will receive an amount equal to $0.125 per Warrant Share for each Warrant issued.

“Each Note shall be accompanied by the issuance by the Company of an unregistered warrant (each, a “Warrant”) to purchase up to a number of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) equal to the principal amount of such Note divided by the Market Price (as defined under Nasdaq regulations) of the Company’s Common Stock on the date of issuance (the “Warrant Shares”). The Company will receive an amount equal to $0.125 per Warrant Share for each Warrant issued.”

Flux Power Holdings, Inc. issued 1,214,769 Common Warrants of warrant to accredited investors for purchase price of $19.369 per Prefunded Warrant for gross proceeds of approximately $5.0 million; paid in cash or cancellation of certain existing debt.

“Amended and Restated Securities Purchase Agreement On September 15, 2025, the Company entered into an amended and restated securities purchase agreement (the “Amended and Restated Purchase Agreement”) with certain of the Initial Purchasers and certain additional investors (collectively, the “Purchasers”) pursuant to which, among other things, the Purchasers agreed to subscribe for and purchase, and the Company agreed to issue and sell to the Purchasers, an aggregate of 258,144 Prefunded Warrants and 1,214,769 Common Warrants at the Purchase Price for gross proceeds of approximately $5.0 million (the “Private Placement”).”

Flux Power Holdings, Inc. issued 258,144 Prefunded Warrants of preferred stock to accredited investors for purchase price of $19.369 per Prefunded Warrant for gross proceeds of approximately $5.0 million; paid in cash or cancellation of certain existing debt.

“Amended and Restated Securities Purchase Agreement On September 15, 2025, the Company entered into an amended and restated securities purchase agreement (the “Amended and Restated Purchase Agreement”) with certain of the Initial Purchasers and certain additional investors (collectively, the “Purchasers”) pursuant to which, among other things, the Purchasers agreed to subscribe for and purchase, and the Company agreed to issue and sell to the Purchasers, an aggregate of 258,144 Prefunded Warrants and 1,214,769 Common Warrants at the Purchase Price for gross proceeds of approximately $5.0 million (the “Private Placement”).”

REED'S, INC. issued 5,000,000 shares of common stock to six accredited investors for $1.00 per Share.

“On September 12, 2025, Reed’s, Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Purchase Agreement ”) with six accredited investors for the issuance and sale in a private placement (the “ Private Placement ”) of 5,000,000 shares (the “ Shares ”) of common stock, $0.0001 par value per share, at a purchase price of $1.00 per Share, for aggregate gross proceeds of $5.0 million.”

Steele Creek Capital Corp issued 11,085.860 shares of common stock for $100,000.00 aggregate, $9.0205 per share.

“On September 2, 2025, the Company sold 11,085.860 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), for an aggregate offering price of $100,000.00, and a per share purchase price of $9.0205.”

BullFrog AI Holdings, Inc. issued the Commitment Shares of common stock to Lincoln Park Capital Fund, LLC.

“The Commitment Shares were issued and the Purchase Shares will be issued and sold by the Company to Lincoln Park in reliance upon the exemptions from the registration requirements of the Securities Act”

BullFrog AI Holdings, Inc. issued up to $10.0 million of the Company’s common stock of common stock to Lincoln Park Capital Fund, LLC for up to $10.0 million aggregate commitment.

“Lincoln Park committed to purchase up to $10.0 million of the Company’s common stock, par value $0.00001 per share”

Nuvve Holding Corp. issued shares of Common Stock underlying the Additional Note and the Additional Warrant (Warrant Shares equal to 100% of conversion shares) of unit to a certain Investor for $111,111.11 principal amount senior convertible promissory note with 10% original issue discount.

“on September 10, 2025, the Company issued to a certain Investor (i) a $111,111.11 principal amount (the “Principal Amount”) senior convertible promissory note, carrying a 10% original issue discount (the “Additional Note”), convertible into shares of Common Stock, and (ii) accompanying warrants (the “Additional Warrant”) to purchase shares of Common Stock (the “AIR Issuance”).”

Marpai, Inc. issued 1,038,519 shares of common stock to three investors, including HillCour Investment Fund, LLC for $1.0592 per share.

“of 1,038,519 shares of its Class A common stock (the “Common Stock”) (of which HillCour purchased 896,903 shares of Common Stock) in a private placement, at a purchase price of $1.0592 per share. The securities issued in the offering are exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”) pursuant to Section”

North Haven Net REIT issued 434,512 Class IO shares and 2,837 Class F-IO shares of securities to a feeder vehicle primarily created to hold certain classes of the Company's common shares for aggregate consideration of approximately $8,856,000 and $58,000.

“As of September 2, 2025, North Haven Net REIT, a Maryland statutory trust (the “Company”), sold an aggregate of 434,512 Class IO shares and 2,837 Class F-IO shares (the "Shares") (with the final number of Shares being determined on September 15, 2025) for aggregate consideration of approximately $8,856,000 and $58,000, respectively, based on the net asset value per share as of August 31, 2025, to a feeder vehicle primarily created to hold certain classes of the Company's common shares.”

Innventure, Inc. issued convertible note to YA II PN, Ltd. (Yorkville) for $10,000,000 in aggregate principal amount.

“stock, par value $0.0001 per share (the “Common Stock”) (as converted, the “Conversion Shares”). Pursuant to the Purchase Agreement, Yorkville purchased, and the Company issued, $10,000,000 in aggregate principal amount of Convertible Debentures (the “Third Convertible Debenture”) on the Agreement Date, upon satisfaction of certain closing conditions in the Purchase”

Black Rock Coffee Bar, Inc. issued 22,011,206 shares of Class C common stock of common stock to Founder Fund Related Parties for nominal consideration.

“Simultaneously with the consummation of the Offering, the Company issued (i) 10,377,136 shares of Class B common stock of the Company, par value $0.00001 per share, to Cynosure Partners 2020, LP, Cynosure Partners 2020 PV, LP, Cynosure Partners 2020 Co-investment, LLC, Cynosure Partners III, LP and certain other Members (as defined in the A&R LLCA), on a one-to-one basis equal to the number of common membership interests of OpCo it owns, in exchange for nominal consideration and (ii) 22,011,206 shares of Class C common stock of the Company, par value $0.00001 per share, to the Founder Fund Related Parties (as defined in the A&R LLCA), on a one-to-one basis equal to the number of common membership interests of OpCo it owns, in exchange for nominal consideration (the “ Exchange ”).”

Black Rock Coffee Bar, Inc. issued 10,377,136 shares of Class B common stock of common stock to Cynosure Partners 2020, LP, Cynosure Partners 2020 PV, LP, Cynosure Partners 2020 Co-investment, LLC, Cynosure Partners III, LP and certain other Members for nominal consideration.

“Simultaneously with the consummation of the Offering, the Company issued (i) 10,377,136 shares of Class B common stock of the Company, par value $0.00001 per share, to Cynosure Partners 2020, LP, Cynosure Partners 2020 PV, LP, Cynosure Partners 2020 Co-investment, LLC, Cynosure Partners III, LP and certain other Members (as defined in the A&R LLCA), on a one-to-one basis equal to the number of common membership interests of OpCo it owns, in exchange for nominal consideration and (ii) 22,011,206 shares of Class C common stock of the Company, par value $0.00001 per share, to the Founder Fund Related Parties (as defined in the A&R LLCA), on a one-to-one basis equal to the number of common membership interests of OpCo it owns, in exchange for nominal consideration (the “ Exchange ”).”

Soluna Holdings, Inc issued up to 2,000,000 shares of Common Stock of warrant to Generate Strategic Credit Master Fund I-B, L.P..

“a pre-funded warrant (the “Pre-Funded Warrant”) to purchase up to 2,000,000 shares of common stock of the Company”

ASTRONICS CORP issued a maximum of 5,125,568 shares of the Company’s common stock of convertible note to initial purchasers for $225.0 million aggregate principal amount.

“On September 16, 2025, Astronics Corporation (the “Company”) issued $225.0 million aggregate principal amount of 0% Convertible Senior Notes due 2031 (the “Notes”).”

Microbot Medical Inc. issued 225,000 shares of Common Stock of common stock to holders of Series H preferred investment options for exercise price per share of $2.10, generating gross proceeds of $472,500.

“On September 8, 2025, the Company issued 225,000 shares of Common Stock upon the exercise of a like number of Series H preferred investment options (the “Series H Options”) by the holders of such options. The exercise price per share of the Series H options was $2.10, generating gross proceeds to the Company, before deducting placement agent fees and expenses, of $472,500”

Microbot Medical Inc. issued preferred investment options to purchase an aggregate of (i) 10,362 shares of Common Stock at an exercise price of $1.875 (ii) 31,429 shares of Common Stock at of warrant to H.C. Wainwright & Co., LLC for cash fee equal to 7.0% of the gross proceeds received by the Company from the Offerings, plus a management fee equal to 1.0% of the gross proceeds.

“shares of the Common Stock issuable upon exercise of the Existing PIOs are registered pursuant to the post-effective amendments on Form S-3 to registration statements on Form S-1 (File Nos. 333-280113 and 333-284688) and the registration statement on Form S-3 (File No. 333-285690), declared effective by the SEC on July 3, 2024, April 2, 2025 and April 1,”

Microbot Medical Inc. issued to purchase up to an aggregate of 13,989,115 shares of Common Stock of warrant to certain holders (the Holders) of existing series F, G, H and I preferred investment options for exercise of Existing PIOs at exercise prices ranging from $1.50 to $2.13 per share.

“the Holder exercised for cash its Existing PIOs to purchase an aggregate of 13,989,115 shares of Common Stock, at exercise prices ranging from $1.50 to $2.13 per share, in consideration for the Company’s agreement to issue new series J preferred investment options (the “New PIOs”) to purchase up to an aggregate of 13,989,115 shares of Common Stock (the “New PIO Shares”) at an exercise price of $4.50 per share”

LIVEPERSON INC issued 26,551 shares of preferred stock to the Noteholders for aggregate payment of $45.0 million in cash, $115.0 million in aggregate principal amount of New Secured Notes, 53,333,947 shares of Common Stock.

“the Company consummated an exchange (the “ Exchange ”) of the $341.1 million in aggregate principal amount of 2026 Notes held by the Noteholders for (i) an aggregate payment of $45.0 million in cash, (ii) $115.0 million in aggregate principal amount of the Company’s 10.0% Second Lien Senior Subordinated Secured Notes due 2029 (the “ New Secured Notes ”), (iii)”

LIVEPERSON INC issued 53,333,947 shares of common stock to the Noteholders for aggregate payment of $45.0 million in cash, $115.0 million in aggregate principal amount of New Secured Notes, 26,551 shares of Series B Preferred Stock.

“the Company consummated an exchange (the “ Exchange ”) of the $341.1 million in aggregate principal amount of 2026 Notes held by the Noteholders for (i) an aggregate payment of $45.0 million in cash, (ii) $115.0 million in aggregate principal amount of the Company’s 10.0% Second Lien Senior Subordinated Secured Notes due 2029 (the “ New Secured Notes ”), (iii)”

Cocrystal Pharma, Inc. issued warrants to acquire up to an aggregate of 207,353 shares of Common Stock of warrant to H.C. Wainwright & Co., LLC for cash fee equal to 7.0% of the aggregate gross proceeds, a management fee equal to 1.0% of the aggregate gross proceeds, reimbursement of certain expenses.

“medicines for use in the treatment of human viral diseases. 2 Under the SPA, no later than October 10, 2025, the Company is required to file a registration statement on Form S-1 registering the resale of the shares of Common Stock issued or issuable upon exercise of the Investor Warrants (the “Resale Registration Statement”). The Company is required to”

Cocrystal Pharma, Inc. issued warrants to purchase up to an aggregate of 5,529,420 shares of warrant to accredited investors for initial exercise price of $1.50 per share.

“and (ii) in a concurrent private placement, warrants to purchase up to an aggregate of 5,529,420 shares of Comon Stock (“the Investor Warrants”), at an initial exercise price of $1.50 per share (the “Private Placement” and together with the Registered Direct Offering, the “Offering”). The Shares were offered at-the-market under rules of The Nasdaq Stock Market,”

Cocrystal Pharma, Inc. issued 2,764,710 shares of common stock to accredited investors for at a price of $1.70 per share.

“in a registered direct offering, an aggregate of 2,764,710 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a price of $1.70 per share (the “Registered Direct Offering”) and (ii) in a concurrent private placement, warrants to purchase up to an aggregate of 5,529,420 shares of Comon Stock (“the Investor”

Solana Co issued pre-funded warrants to purchase shares of Common Stock of warrant to accredited investors for $6.881 less $0.001.

“pre-funded warrants (the “ Cash Pre-Funded Warrants ”) to purchase shares of the Common Stock (the “ Cash Pre-Funded Warrant Shares ”) at an offering price of the Per Share Cash Purchase Price less $0.001 per Cash Pre-Funded Warrant”

Solana Co issued shares of Class A common stock of common stock to accredited investors for $6.881 per Cash Share.

“the Company agreed to sell and issue to the Cash Purchasers in a private placement offering (the “ Cash Offering ”) an aggregate offering of (i) either shares (the “ Cash Shares ”) of Class A common stock of the Company, par value $0.001 per share (the “ Common Stock ”) at an offering price of $6.881 per Cash Share”

AMERICAN REBEL HOLDINGS INC issued 18,800 shares of Series D Convertible Preferred Stock of preferred stock to accredited investors or an officer of the Company for commitment fee to the Seller.

“18,800 shares of Series D Convertible Preferred Stock for the commitment fee to the Seller”

AMERICAN REBEL HOLDINGS INC issued 280,000 shares of Series D Convertible Preferred Stock of preferred stock to accredited investors or an officer of the Company for purchase of 30% of the outstanding membership interests in the Seller.

“On September 15, 2025, the Company issued 280,000 shares of Series D Convertible Preferred Stock for the purchase of 30% of the outstanding membership interests in the Seller set forth in Item 1.01 above”

Edgemode, Inc. issued convertible note to an accredited investor for $68,000 net proceeds.

“On September 9, 2025, Edgemode, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Promissory Note Purchase Agreement”) with an accredited investor (the “Investor”), pursuant to which the Company sold the Investor an unsecured original issue discount promissory note in the principal amount of $81,600 (the “Promissory Note”) for which the Company received net proceeds of $68,000.”

Serina Therapeutics, Inc. issued 100% of the number of shares issuable upon conversion of the funds extended by the investors on such funding date of warrant to Gregory H. Bailey, M.D. for exercise price equal to $5.44 per share.

“equal to 100% of the number of shares issuable upon conversion of the funds extended by the investors on such funding date. Such warrants will have an exercise price equal to $5.44 per share. The warrants expire on the earlier of sixty days following the achievement of Milestone 5 or September 30, 2026, unless stockholder approval has not been obtained as”

Serina Therapeutics, Inc. issued convertible note to Gregory H. Bailey, M.D. for aggregate principal amount of up to $20 million.

“note (the “Convertible Note”) with Gregory H. Bailey, M.D., a member of the Company’s Board of Directors, making available to the Company an aggregate principal amount of up to $20 million. Under the Convertible Note, borrowings may be drawn in the discretion of the Company in five tranches tied to certain clinical and operational milestones, provided that if at”

REVELATION BIOSCIENCES, INC. issued 13,065,000 new common stock warrants (the "Class I Common Stock Warrants") of warrant to certain holders of existing Class H Common Stock Warrants for exercise of Existing Warrants at $2.20 per share for aggregate gross proceeds of approximately $9.6 million.

“On September 10, 2025, Revelation Biosciences, Inc. (the “Company”) entered into warrant exercise inducement offer letters (the “Inducement Letters”) with certain holders (the “Holders”) of 13,065,000 existing Class H Common Stock Warrants exercisable for an aggregate of 4,355,000 shares of its common stock (collectively, the “Existing Warrants”), to exercise their warrants at an exercise price of $2.20 per share, in exchange for the Company’s agreement to issue 13,065,000 new common stock warrants (the “Class I Common Stock Warrants”) as described below.”

Enovix Corp issued Initially, a maximum of 39,344,256 shares of the Company’s Common Stock may be issued upon conversion of the Notes based on the initial maximum conversion rate of convertible note to initial purchasers for $360 million aggregate principal amount of 4.75% Convertible Senior Notes due 2030.

“accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 1.01 Entry into a Material Definitive Agreement. Indenture and Notes On September 10, 2025, Enovix Corporation (the “ Company ”) completed its previously announced private offering (the “ Offering ”) of $360 million aggregate principal amount of 4.75% Convertible Senior”

Bolt Projects Holdings, Inc. issued up to $20.0 million of the Company's common stock of common stock to Ascent Partners Fund LLC.

“the Company will have the right from time to time at its option to sell to the Investor up to $20.0 million of the Company's common stock”

Bolt Projects Holdings, Inc. issued 85,588 shares of Common Stock of common stock to Ascent Partners Fund LLC for irrevocable commitment to purchase.

“the Company agreed to issue 85,588 shares of Common Stock to the Investor (the "Upfront Commitment Shares")”

Kodiak AI, Inc. issued shares of Kodiak Series A Preferred Stock and PIPE Warrants of preferred stock to certain institutional and accredited investors for aggregate purchase price of $145 million.

“the proposed business combination. As of September 15, 2025, AACT has entered into a Subscription Agreement with certain Preferred Investors for an aggregate purchase price of $145 million. One of such Preferred Investors previously entered into a subscription agreement for an aggregate purchase price of $50 million in connection with AACT’s previously announced”

INSPIRE VETERINARY PARTNERS, INC. issued related Warrants of warrant to certain institutional investors for gross proceeds of approximately $1.0 million.

“the Company and certain investors effected an Additional Closing (as defined in the Securities Purchase Agreement), with respect to 1,253 additional shares of Series B Preferred Stock and related Warrants for gross proceeds of approximately $1.0 million.”

INSPIRE VETERINARY PARTNERS, INC. issued 1,253 additional shares of Series B Preferred Stock of preferred stock to certain institutional investors for gross proceeds of approximately $1.0 million.

“the Company and certain investors effected an Additional Closing (as defined in the Securities Purchase Agreement), with respect to 1,253 additional shares of Series B Preferred Stock and related Warrants for gross proceeds of approximately $1.0 million.”

Silexion Therapeutics Corp issued 450,000 ordinary shares of common stock to Moringa Sponsor, LP for $1.8 million of the outstanding amount under the Amended and Restated Promissory Note.

“On September 15, 2025, Silexion Therapeutics Corp, a Cayman Islands exempted company (“ Silexion ” or the “ Company ”) issued 450,000 ordinary shares, par value $0.0135 per share, of Silexion (“ ordinary shares ”), to Moringa Sponsor, LP (the “ Sponsor ”) upon conversion by Silexion of an aggregate of $1.8 million of the outstanding amount under the Amended and Restated Promissory Note, dated August 15, 2024, in an original principal amount of $3.4 million (the “ Sponsor Convertible Note ”), issued by Silexion to the Sponsor.”

Apollo Origination II (UL) Capital Trust issued 1,508,864.58 of common stock to certain investors for $40,000,000.

“The following table details the amount of Shares sold and consideration therefor: Date of Unregistered Sale Amount of Shares Consideration September 11, 2025 1,508,864.58 $ 40,000,000 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned”